Cambridge, MA, United States of America

Jason M Lajoie

USPTO Granted Patents = 7 

Average Co-Inventor Count = 7.0

ph-index = 4

Forward Citations = 44(Granted Patents)


Location History:

  • Cambridge, MA (US) (2019 - 2020)
  • Brighton, MA (US) (2023)

Company Filing History:


Years Active: 2019-2023

Loading Chart...
7 patents (USPTO):Explore Patents

Title: Jason M Lajoie: Innovator in Cancer Treatment

Introduction

Jason M Lajoie is a prominent inventor based in Cambridge, MA, known for his significant contributions to the field of cancer treatment. With a total of seven patents to his name, Lajoie's work focuses on developing innovative therapeutic solutions that target critical pathways in cancer biology.

Latest Patents

Among his latest patents is a groundbreaking invention related to agonist antibodies that bind human CD137. This patent outlines compounds, such as antibodies or antigen-binding fragments, that interact with an epitope of CD137, effectively agonizing this receptor. The implications of this work are profound, as it provides methods for treating or ameliorating symptoms associated with cancer.

Career Highlights

Lajoie has established himself as a key figure in the biotechnology sector, particularly through his role at Compass Therapeutics LLC. His expertise in antibody development and cancer therapeutics has positioned him as a leader in the field, contributing to advancements that may significantly improve patient outcomes.

Collaborations

Throughout his career, Lajoie has collaborated with notable colleagues, including Piotr Bobrowicz and Paul Widboom. These partnerships have fostered a collaborative environment that enhances innovation and accelerates the development of new therapeutic strategies.

Conclusion

Jason M Lajoie's work exemplifies the spirit of innovation in the fight against cancer. His patents and collaborations reflect a commitment to advancing medical science and improving the lives of patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…